Download PDF
Semin Liver Dis 2017; 37(04): 343-362
DOI: 10.1055/s-0037-1607453
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Salvage Therapies for Autoimmune Hepatitis: A Critical Review

Stuart K. Roberts
1   Department of Gastroenterology, The Alfred Hospital and Monash University, Melbourne, Australia
,
William Kemp
1   Department of Gastroenterology, The Alfred Hospital and Monash University, Melbourne, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

    Permissions and Reprints

Abstract

Several salvage therapies have been identified for autoimmune hepatitis refractory or recalcitrant to conventional therapy; however, the optimal salvage strategy remains unclear. High-dose prednisolone is currently recommended as the front-line salvage therapy, with alternative immunosuppressive therapies reserved for continuing treatment failure. Of the second-line therapies, the calcineurin inhibitors, cyclosporine and tacrolimus, and mycophenolate mofetil are preferred and have the most accrued clinical data. However, none of these have undergone rigorous clinical evaluation via randomized clinical trials. Tacrolimus is generally preferred over cyclosporine because of its higher potency and increased utility in organ transplantation. Mycophenolate is particularly useful for azathioprine intolerance but also for nonresponse to standard treatment. Subjects with progressive liver failure should undergo liver transplantation evaluation. The appropriate timing, dosing, and monitoring of salvage therapies require determination. Several promising immunosuppressive therapies have been developed for autoimmune diseases including molecular agents that may enhance regulatory T cell activity and function.

Keywords

autoimmune hepatitis - cyclosporine - tacrolimus - mycophenolate

Funding

None.


 

  • References

  • 1 Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354 (01) 54-66
    CrossrefPubMedGoogle Scholar
  • 2 Werner M, Prytz H, Ohlsson B. , et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43 (10) 1232-1240
    CrossrefPubMedGoogle Scholar
  • 3 Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60 (03) 612-617
    CrossrefPubMedGoogle Scholar
  • 4 Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33 (01) 99-103
    CrossrefPubMedGoogle Scholar
  • 5 Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol 2010; 16 (08) 934-947
    CrossrefPubMedGoogle Scholar
  • 6 Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139 (01) 58-72.e4
    CrossrefPubMedGoogle Scholar
  • 7 Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110 (03) 848-857
    CrossrefPubMedGoogle Scholar
  • 8 Hoeroldt B, McFarlane E, Dube A. , et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140 (07) 1980-1989
    CrossrefPubMedGoogle Scholar
  • 9 Delgado JS, Vodonos A, Malnick S. , et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis 2013; 14 (11) 611-618
    PubMedGoogle Scholar
  • 10 Manns MP, Czaja AJ, Gorham JD. , et al; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51 (06) 2193-2213
    CrossrefPubMedGoogle Scholar
  • 11 European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015; 63 (04) 971-1004
    CrossrefPubMedGoogle Scholar
  • 12 Gleeson D, Heneghan MA. ; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60 (12) 1611-1629
    CrossrefPubMedGoogle Scholar
  • 13 Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40 (158) 159-185
    PubMedGoogle Scholar
  • 14 Soloway RD, Summerskill WH, Baggenstoss AH. , et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63 (05) 820-833
    PubMedGoogle Scholar
  • 15 Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1 (7806): 735-737
    PubMedGoogle Scholar
  • 16 Lamers MM, van Oijen MGH, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010; 53 (01) 191-198
    CrossrefPubMedGoogle Scholar
  • 17 Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16 (11) 876-883
    CrossrefPubMedGoogle Scholar
  • 18 Manns MP, Woynarowski M, Kreisel W. , et al; European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139 (04) 1198-1206
    CrossrefPubMedGoogle Scholar
  • 19 Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42 (01) 53-62
    CrossrefPubMedGoogle Scholar
  • 20 Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46 (04) 1138-1145
    CrossrefPubMedGoogle Scholar
  • 21 Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4 (04) 622-627
    CrossrefPubMedGoogle Scholar
  • 22 Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78 (03) 518-523
    PubMedGoogle Scholar
  • 23 van Gerven NM, Verwer BJ, Witte BI. , et al; Dutch Autoimmune Hepatitis Working Group. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58 (01) 141-147
    CrossrefPubMedGoogle Scholar
  • 24 Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008; 7 (03) 319-333
    CrossrefPubMedGoogle Scholar
  • 25 Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 92 (01) 215-219
    CrossrefPubMedGoogle Scholar
  • 26 Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45 (04) 584-591
    CrossrefPubMedGoogle Scholar
  • 27 Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. J Autoimmun 2016; 75: 6-19
    CrossrefPubMedGoogle Scholar
  • 28 Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008; 14 (21) 3306-3312
    CrossrefPubMedGoogle Scholar
  • 29 Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004; 53 (04) 599-608
    CrossrefPubMedGoogle Scholar
  • 30 Strettell MD, Donaldson PT, Thomson LJ. , et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112 (06) 2028-2035
    CrossrefPubMedGoogle Scholar
  • 31 de Boer YS, van Gerven NM, Zwiers A. , et al; Dutch Autoimmune Hepatitis Study Group; LifeLines Cohort Study; Study of Health in Pomerania. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014; 147 (02) 443-452.e5
    CrossrefPubMedGoogle Scholar
  • 32 Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011; 25 (06) 653-664
    CrossrefPubMedGoogle Scholar
  • 33 Björnsson E, Talwalkar J, Treeprasertsuk S. , et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51 (06) 2040-2048
    CrossrefPubMedGoogle Scholar
  • 34 Liberal R, Grant CR, Holder BS. , et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology 2015; 62 (03) 863-875
    CrossrefPubMedGoogle Scholar
  • 35 Grant CR, Liberal R, Holder BS. , et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 2014; 59 (03) 1007-1015
    CrossrefPubMedGoogle Scholar
  • 36 Kirstein MM, Metzler F, Geiger E. , et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 2015; 62 (05) 1524-1535
    CrossrefPubMedGoogle Scholar
  • 37 Ngu JH, Gearry RB, Frampton CM, Stedman CA. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 2013; 57 (06) 2399-2406
    CrossrefPubMedGoogle Scholar
  • 38 Yoshizawa K, Matsumoto A, Ichijo T. , et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 2012; 56 (02) 668-676
    CrossrefPubMedGoogle Scholar
  • 39 Werner M, Wallerstedt S, Lindgren S. , et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010; 45 (04) 457-467
    CrossrefPubMedGoogle Scholar
  • 40 Tan P, Marotta P, Ghent C, Adams P. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int 2005; 25 (04) 728-733
    CrossrefPubMedGoogle Scholar
  • 41 Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51 (01) 161-167
    CrossrefPubMedGoogle Scholar
  • 42 Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27 (04) 507-515
    CrossrefPubMedGoogle Scholar
  • 43 Kerkar N, Annunziato RA, Foley L. , et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006; 43 (05) 629-634
    CrossrefPubMedGoogle Scholar
  • 44 Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol 2008; 14 (21) 3360-3367
    CrossrefPubMedGoogle Scholar
  • 45 Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43 (03) 532-538
    CrossrefPubMedGoogle Scholar
  • 46 Ichai P, Duclos-Vallée JC, Guettier C. , et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13 (07) 996-1003
    CrossrefPubMedGoogle Scholar
  • 47 Yeoman AD, Westbrook RH, Zen Y. , et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53 (03) 926-934
    CrossrefPubMedGoogle Scholar
  • 48 Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95 (02) 448-453
    CrossrefPubMedGoogle Scholar
  • 49 Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15 (02) 215-221
    CrossrefPubMedGoogle Scholar
  • 50 Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976; 8 (03) 221-227
    PubMedGoogle Scholar
  • 51 Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007; 4 (04) 202-214
    CrossrefPubMedGoogle Scholar
  • 52 Weiler-Normann C, Lohse AW. Acute autoimmune hepatitis: many open questions. J Hepatol 2014; 61 (04) 727-729
    CrossrefPubMedGoogle Scholar
  • 53 Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis--Update 2015. J Hepatol 2015; 62 (1, Suppl) S100-S111
    CrossrefPubMedGoogle Scholar
  • 54 Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8 (06) 585-590
    PubMedGoogle Scholar
  • 55 Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119 (05) 1312-1316
    CrossrefPubMedGoogle Scholar
  • 56 Zandieh I, Krygier D, Wong V. , et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008; 22 (04) 388-392
    CrossrefPubMedGoogle Scholar
  • 57 Csepregi A, Röcken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12 (09) 1362-1366
    CrossrefPubMedGoogle Scholar
  • 58 Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 1995; 50 (02) 317-333
    CrossrefPubMedGoogle Scholar
  • 59 Deflazacort--an alternative to prednisolone?. Drug Ther Bull 1999; 37 (08) 57-58
    CrossrefPubMedGoogle Scholar
  • 60 Rebollo Bernárdez J, Cifuentes Mimoso C, Piñar Moreno A. , et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis [Article in English, Spanish]. Rev Esp Enferm Dig 1999; 91 (09) 630-638
    PubMedGoogle Scholar
  • 61 de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4 (12) 686-694
    PubMedGoogle Scholar
  • 62 Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr A 1992; 583 (01) 83-90
    CrossrefPubMedGoogle Scholar
  • 63 Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29 (4 Pt 2): 601-605
    PubMedGoogle Scholar
  • 64 Dubinsky MC, Lamothe S, Yang HY. , et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118 (04) 705-713
    CrossrefPubMedGoogle Scholar
  • 65 Dhaliwal HK, Anderson R, Thornhill EL. , et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012; 56 (04) 1401-1408
    CrossrefPubMedGoogle Scholar
  • 66 Sparrow MP, Hande SA, Friedman S. , et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22 (05) 441-446
    CrossrefPubMedGoogle Scholar
  • 67 Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5 (02) 209-214
    CrossrefPubMedGoogle Scholar
  • 68 de Boer YS, van Gerven NM, de Boer NK, Mulder CJ, Bouma G, van Nieuwkerk CM. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2013; 37 (06) 640-646
    CrossrefPubMedGoogle Scholar
  • 69 Al-Shamma S, Eross B, Mclaughlin S. Use of a xanthine oxidase inhibitor in autoimmune hepatitis. Hepatology 2013; 57 (03) 1281-1282
    CrossrefPubMedGoogle Scholar
  • 70 Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can't live without. J Immunol 2013; 191 (12) 5785-5791
    CrossrefPubMedGoogle Scholar
  • 71 Liberal R, de Boer YS, Andrade RJ. , et al; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther 2017; 45 (05) 723-732
    CrossrefPubMedGoogle Scholar
  • 72 Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985; 143 (10) 463-465
    PubMedGoogle Scholar
  • 73 Nasseri-Moghaddam S, Nikfam S, Karimian S, Khashayar P, Malekzadeh R. Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial. Middle East J Dig Dis 2013; 5 (04) 193-200
    PubMedGoogle Scholar
  • 74 Alvarez F, Ciocca M, Cañero-Velasco C. , et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30 (02) 222-227
    CrossrefPubMedGoogle Scholar
  • 75 Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46 (06) 1321-1327
    CrossrefPubMedGoogle Scholar
  • 76 Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135 (01) 111-114
    CrossrefPubMedGoogle Scholar
  • 77 Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93 (04) 890-893
    CrossrefPubMedGoogle Scholar
  • 78 Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17 (04) 317-320
    CrossrefPubMedGoogle Scholar
  • 79 Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21 (06) 1040-1047
    CrossrefPubMedGoogle Scholar
  • 80 Senturk H. Treatment of corticosteroid-azathioprine resistant autoimmune hepatitis with cyclosporin A. Indian J Gastroenterol 1995; 14 (03) 110-111
    PubMedGoogle Scholar
  • 81 Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36 (03) 459-461
    CrossrefPubMedGoogle Scholar
  • 82 Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94 (01) 241-248
    CrossrefPubMedGoogle Scholar
  • 83 Czaja AJ. Drug choices in autoimmune hepatitis: part B--Nonsteroids. Expert Rev Gastroenterol Hepatol 2012; 6 (05) 617-635
    CrossrefPubMedGoogle Scholar
  • 84 Ascha M, Hanouneh M, Zein N, McCullough A, Hanouneh I. The utility of tacrolimus in the management of adults with difficult-to-treat autoimmune hepatitis: review of literature. Am J Gastroenterol 2016; 111: S385-S385
    PubMedGoogle Scholar
  • 85 Van Thiel DH, Wright H, Carroll P. , et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90 (05) 771-776
    PubMedGoogle Scholar
  • 86 Than NN, Wiegard C, Weiler-Normann C. , et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scand J Gastroenterol 2016; 51 (03) 329-336
    CrossrefPubMedGoogle Scholar
  • 87 Efe C, Hagström H, Ytting H. , et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2017; (Epub ahead of print) DOI: 10.1016/j.cgh.2017.06.001.
    CrossrefPubMedGoogle Scholar
  • 88 Tannous MM, Cheng J, Muniyappa K. , et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011; 34 (03) 405-407
    CrossrefPubMedGoogle Scholar
  • 89 Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38 (09) 805-809
    CrossrefPubMedGoogle Scholar
  • 90 Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13 (23) 3232-3236
    CrossrefPubMedGoogle Scholar
  • 91 Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 (Suppl. 01) s2-s8
    CrossrefPubMedGoogle Scholar
  • 92 Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?. Autoimmun Rev 2007; 6 (03) 190-195
    CrossrefPubMedGoogle Scholar
  • 93 Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Expert Rev Gastroenterol Hepatol 2011; 5 (04) 517-522
    CrossrefPubMedGoogle Scholar
  • 94 Schuppan D, Herold C, Strobel D, Schneider H, Hahn E. Successful treatment of therapy-refractory autoimmune hepatitis with mycophenolate mofetil. (abstract) Hepatology 1998; 28: A1960
    PubMedGoogle Scholar
  • 95 Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33 (03) 371-375
    CrossrefPubMedGoogle Scholar
  • 96 Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18 (05) 321-326
    CrossrefPubMedGoogle Scholar
  • 97 Brunt EM, Di Bisceglie AM. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum Pathol 2004; 35 (04) 509-512
    CrossrefPubMedGoogle Scholar
  • 98 Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39 (09) 819-825
    CrossrefPubMedGoogle Scholar
  • 99 Inductivo-Yu I, Adams A, Gish RG. , et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5 (07) 799-802
    CrossrefPubMedGoogle Scholar
  • 100 Hlivko JT, Shiffman ML, Stravitz RT. , et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6 (09) 1036-1040
    CrossrefPubMedGoogle Scholar
  • 101 Hennes EM, Oo YH, Schramm C. , et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am J Gastroenterol 2008; 103 (12) 3063-3070
    CrossrefPubMedGoogle Scholar
  • 102 Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009; 54 (11) 2519-2522
    CrossrefPubMedGoogle Scholar
  • 103 Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51 (01) 156-160
    CrossrefPubMedGoogle Scholar
  • 104 Chatur N, Ramji A, Bain VG. , et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25 (04) 723-727
    CrossrefPubMedGoogle Scholar
  • 105 Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24 (10) 588-592
    CrossrefPubMedGoogle Scholar
  • 106 Baven-Pronk AM, Coenraad MJ, van Buuren HR. , et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34 (03) 335-343
    CrossrefPubMedGoogle Scholar
  • 107 Park SW, Um SH, Lee HA. , et al. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis. Clin Mol Hepatol 2016; 22 (02) 281-285
    CrossrefPubMedGoogle Scholar
  • 108 Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2014; 15 (12) 1715-1736
    CrossrefPubMedGoogle Scholar
  • 109 Czaja AJ. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol 2012; 26 (09) 615-620
    CrossrefPubMedGoogle Scholar
  • 110 Brown EJ, Albers MW, Shin TB. , et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369 (6483): 756-758
    CrossrefPubMedGoogle Scholar
  • 111 Roberts SK, Lim R, Strasser S. , et al. Mycophenolate mofetil in autoimmune hepatitis patients with suboptimal outcomes to standard therapy: the Tapestry study. Clin Gastro Hepatol 2017; DOI: 10.1016/j.cgh.2017.09.063. . [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 112 Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18 (16) 1926-1945
    CrossrefPubMedGoogle Scholar
  • 113 Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124 (03) 471-484
    CrossrefPubMedGoogle Scholar
  • 114 Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006; 81 (03) 445-454
    CrossrefPubMedGoogle Scholar
  • 115 Molhoek KR, McSkimming CC, Olson WC, Brautigan DL, Slingluff Jr CL. Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother 2009; 58 (06) 867-876
    CrossrefPubMedGoogle Scholar
  • 116 Vierling JM. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol 2015; 13 (12) 2088-2108
    CrossrefPubMedGoogle Scholar
  • 117 Kerkar N, Dugan C, Rumbo C. , et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005; 5 (05) 1085-1089
    CrossrefPubMedGoogle Scholar
  • 118 Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med 2014; 127 (11) 1128-1131
    CrossrefPubMedGoogle Scholar
  • 119 Kurowski J, Melin-Aldana H, Bass L, Alonso EM, Ekong UD. Sirolimus as rescue therapy in pediatric autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2014; 58 (01) e4-e6
    CrossrefPubMedGoogle Scholar
  • 120 Veroux M, Tallarita T, Corona D, D'Assoro A, Gurrieri C, Veroux P. Sirolimus in solid organ transplantation: current therapies and new frontiers. Immunotherapy 2011; 3 (12) 1487-1497
    CrossrefPubMedGoogle Scholar
  • 121 Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67 (03) 369-391
    CrossrefPubMedGoogle Scholar
  • 122 Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol 2015; 50 (08) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 123 Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92 (06) 2675-2682
    CrossrefPubMedGoogle Scholar
  • 124 Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20 (03) 190-200
    CrossrefPubMedGoogle Scholar
  • 125 Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997; 126 (09) 682-688
    CrossrefPubMedGoogle Scholar
  • 126 Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999; 117 (05) 1173-1180
    CrossrefPubMedGoogle Scholar
  • 127 Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29 (06) 990-993
    CrossrefPubMedGoogle Scholar
  • 128 Venkataramani A, Jones MB, Sorrell MF. Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastroenterol 2001; 96 (12) 3432-3434
    CrossrefPubMedGoogle Scholar
  • 129 Haridy J, Nicoll A, Sood S. Methotrexate therapy for autoimmune hepatitis. Clin Gastroenterol Hepatol 2017; DOI: 10.1016/j.cgh.2017.07.003. . [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 130 Ksouda K, Affes H, Atheymen R, Ezzeddine M, Zeghal K, Hammami S. Autoimmune hepatitis as an adverse effect of long-term methotrexate therapy. Indian J Pharmacol 2014; 46 (06) 649-650
    CrossrefPubMedGoogle Scholar
  • 131 Moreno-Otero R, García-Buey L, García-Sanchez A, Trapero-Marugán M. Autoimmune hepatitis after long-term methotrexate therapy for rheumatoid arthritis. Curr Drug Saf 2011; 6 (03) 197-200
    CrossrefPubMedGoogle Scholar
  • 132 Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010; 28 (03) 508-518
    CrossrefPubMedGoogle Scholar
  • 133 Lewis JH, Schiff E. ; American College of Gastroenterology. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on FDA-related matters. Am J Gastroenterol 1988; 83 (12) 1337-1345
    PubMedGoogle Scholar
  • 134 Curtis JR, Beukelman T, Onofrei A. , et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69 (01) 43-47
    CrossrefPubMedGoogle Scholar
  • 135 Kanzler S, Gerken G, Dienes HP, Meyer zum Büschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases. Z Gastroenterol 1997; 35 (07) 571-578
    PubMedGoogle Scholar
  • 136 Greten TF, Ormandy LA, Fikuart A. , et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010; 33 (02) 211-218
    CrossrefPubMedGoogle Scholar
  • 137 Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999; 117 (03) 645-652
    CrossrefPubMedGoogle Scholar
  • 138 Weiler-Normann C, Schramm C, Quaas A. , et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58 (03) 529-534
    CrossrefPubMedGoogle Scholar
  • 139 Borman MA, Urbanski S, Swain MG. Anti-TNF-induced autoimmune hepatitis. J Hepatol 2014; 61 (01) 169-170
    CrossrefPubMedGoogle Scholar
  • 140 Burak KW, Swain MG, Santodomingo-Garzon T. , et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013; 27 (05) 273-280
    CrossrefPubMedGoogle Scholar
  • 141 Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994; 121 (03) 207-218
    CrossrefPubMedGoogle Scholar
  • 142 Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11 (01) 12-15
    CrossrefPubMedGoogle Scholar
  • 143 Yoshikawa M, Tsujii T, Matsumura K. , et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16 (02) 358-364
    CrossrefPubMedGoogle Scholar
  • 144 Gianni L, Di Padova F, Zuin M, Podda M. Bile acid-induced inhibition of the lymphoproliferative response to phytohemagglutinin and pokeweed mitogen: an in vitro study. Gastroenterology 1980; 78 (02) 231-235
    PubMedGoogle Scholar
  • 145 Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101 (12) 2790-2799
    CrossrefPubMedGoogle Scholar
  • 146 Nakamura K, Yoneda M, Yokohama S. , et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13 (05) 490-495
    CrossrefPubMedGoogle Scholar
  • 147 Heathcote J. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. (editorial) J Gastroenterol Hepatol 1998; 13 (05) 457-459
    CrossrefPubMedGoogle Scholar
  • 148 Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30 (06) 1381-1386
    CrossrefPubMedGoogle Scholar
  • 149 Szczepiorkowski ZM, Winters JL, Bandarenko N. , et al; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25 (03) 83-177
    CrossrefPubMedGoogle Scholar
  • 150 Liu LL, Feng ML, Wang LN, Li XL, Yao L. A case report of successful treatment with plasma exchange for adult-onset Still's disease with autoimmune hepatitis. J Clin Apher 2010; 25 (02) 74-76
    PubMedGoogle Scholar
  • 151 Suzuki K, Matsuki Y, Hidaka T. , et al. Double filtration plasmapheresis in a patient with autoimmune hepatitis-systemic lupus erythematosus overlap. Intern Med 1993; 32 (09) 725-729
    CrossrefPubMedGoogle Scholar
  • 152 Lobzin U, Murtazina R, Goriacheyva L. , et al. Double filtration plasmapheresis in pediatrics. Therapeutic Apheresis and Dialysis. Conference Vienna, Austria. Conference Publication 2011; 15: A19
    PubMedGoogle Scholar
  • 153 Dumortier J, Scoazec JY, Guillaud O, Hequet O, Hervieu V, Boillot O. Treatment of severe refractory de novo auto-immune hepatitis after liver transplantation with plasmapheresis. Clin Res Hepatol Gastroenterol 2015; 39 (06) e83-e85
    CrossrefPubMedGoogle Scholar
  • 154 Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2 (07) 625-631
    CrossrefPubMedGoogle Scholar
  • 155 Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl 2013; 19 (10) 1065-1077
    PubMedGoogle Scholar
  • 156 Ilyas JA, O'Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011; 25 (06) 765-782
    CrossrefPubMedGoogle Scholar
  • 157 Schramm C, Bubenheim M, Adam R. , et al; European Liver Intestine Transplant Association. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010; 16 (04) 461-469
    PubMedGoogle Scholar
  • 158 Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS liver transplant registry. Clin Transpl 2004; 315-329
    PubMedGoogle Scholar
  • 159 Ratziu V, Samuel D, Sebagh M. , et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999; 30 (01) 131-141
    CrossrefPubMedGoogle Scholar
  • 160 Birnbaum AH, Benkov KJ, Pittman NS, McFarlane-Ferreira Y, Rosh JR, LeLeiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997; 25 (01) 20-25
    PubMedGoogle Scholar
  • 161 González-Koch A, Czaja AJ, Carpenter HA. , et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001; 7 (04) 302-310
    CrossrefPubMedGoogle Scholar
  • 162 Vogel A, Heinrich E, Bahr MJ. , et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18 (01) 62-69
    CrossrefPubMedGoogle Scholar
  • 163 Campsen J, Zimmerman MA, Trotter JF. , et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008; 14 (09) 1281-1286
    CrossrefPubMedGoogle Scholar
  • 164 Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12 (12) 1813-1824
    CrossrefPubMedGoogle Scholar
  • 165 Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15 (10) 1254-1261
    CrossrefPubMedGoogle Scholar
  • 166 Duclos-Vallée JC, Sebagh M, Rifai K. , et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003; 52 (06) 893-897
    CrossrefPubMedGoogle Scholar
  • 167 Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68 (02) 253-256
    CrossrefPubMedGoogle Scholar
  • 168 Hurtova M, Duclos-Vallée JC, Johanet C. , et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl 2001; 7 (06) 556-558
    CrossrefPubMedGoogle Scholar
  • 169 Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011; 17 (29) 3120-3140
    CrossrefPubMedGoogle Scholar
  • 170 Longhi MS, Meda F, Wang P. , et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008; 47 (02) 581-591
    CrossrefPubMedGoogle Scholar
  • 171 Nagler A, Pines M, Abadi U. , et al. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology 2000; 31 (03) 641-648
    CrossrefPubMedGoogle Scholar
  • 172 Cai Q, Du X, Zhou B, Cai C, Kermany MH, Yoo T. Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease. ORL J Otorhinolaryngol Relat Spec 2009; 71 (03) 135-141
    CrossrefPubMedGoogle Scholar
  • 173 Gonnella PA, Del Nido PJ, McGowan FX. Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of STAT 6 genes in BALB/CJ mice. J Clin Immunol 2009; 29 (04) 434-443
    CrossrefPubMedGoogle Scholar
  • 174 Tutaj M, Szczepanik M. Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun 2007; 28 (04) 208-215
    CrossrefPubMedGoogle Scholar
  • 175 Blumenfeld HJ, Tohn R, Haeryfar SM, Liu Y, Savage PB, Delovitch TL. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol 2011; 166 (01) 121-133
    CrossrefPubMedGoogle Scholar
  • 176 Kuo TK, Hung SP, Chuang CH. , et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 2008; 134 (07) 2111-2121 , 2121.e1–2121.e3
    CrossrefPubMedGoogle Scholar
  • 177 Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008; 223: 143-155
    CrossrefPubMedGoogle Scholar
  • 178 Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009; 104 (04) 276-284
    CrossrefPubMedGoogle Scholar
  • 179 Fiocco U, Sfriso P, Oliviero F. , et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 2008; 8 (01) 76-82
    CrossrefPubMedGoogle Scholar
  • 180 Ben-Shoshan M. CTLA-4Ig: uses and future directions. Recent Pat Inflamm Allergy Drug Discov 2009; 3 (02) 132-142
    CrossrefPubMedGoogle Scholar
  • 181 Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009; (04) CD007277
    PubMedGoogle Scholar
  • 182 Viglietta V, Bourcier K, Buckle GJ. , et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008; 71 (12) 917-924
    CrossrefPubMedGoogle Scholar
  • 183 Guinan EC, Boussiotis VA, Neuberg D. , et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340 (22) 1704-1714
    CrossrefPubMedGoogle Scholar
  • 184 Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol 2012; 68 (05) 895-898
    CrossrefPubMedGoogle Scholar
  • 185 van Gerven NM, de Boer YS, Zwiers A. , et al; Dutch Autoimmune Hepatitis Study group. Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. Liver Int 2013; 33 (07) 1039-1043
    CrossrefPubMedGoogle Scholar
  • 186 Chinen T, Kannan AK, Levine AG. , et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol 2016; 17 (11) 1322-1333
    CrossrefPubMedGoogle Scholar
  • 187 Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15 (05) 283-294
    CrossrefPubMedGoogle Scholar
  • 188 Jeffery H, Jeffery LE, Adams DH. , et al. Low dose proleukin promotes enhanced regulatory phenotype with selective induction of phosphoSTAT5 and prosurvival Bcl-2 in blood and liver Treg in autoimmune liver disease. Eur J Immunol 2016; 46: 103
    PubMedGoogle Scholar
  • 189 Drazan KE, Wu L, Bullington D, Shaked A. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg 1996; 31 (03) 411-414
    CrossrefPubMedGoogle Scholar
  • 190 Skapenko A, Niedobitek GU, Kalden JR, Lipsky PE, Schulze-Koops H. Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol 2004; 172 (10) 6427-6434
    CrossrefPubMedGoogle Scholar
  • 191 Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996; 39 (06) 836-845
    CrossrefPubMedGoogle Scholar
  • 192 Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998; 28 (06) 1597-1606
    CrossrefPubMedGoogle Scholar
  • 193 McHutchison JG, Giannelli G, Nyberg L. , et al. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J Interferon Cytokine Res 1999; 19 (11) 1265-1270
    CrossrefPubMedGoogle Scholar
  • 194 Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118 (04) 655-660
    CrossrefPubMedGoogle Scholar
  • 195 Nelson DR, Tu Z, Soldevila-Pico C. , et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38 (04) 859-868
    CrossrefPubMedGoogle Scholar
  • 196 Fuchs AC, Granowitz EV, Shapiro L. , et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol 1996; 16 (05) 291-303
    CrossrefPubMedGoogle Scholar
  • 197 Huhn RD, Radwanski E, O'Connell SM. , et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87 (02) 699-705
    PubMedGoogle Scholar
  • 198 Huhn RD, Radwanski E, Gallo J. , et al. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther 1997; 62 (02) 171-180
    CrossrefPubMedGoogle Scholar
  • 199 Barnea ER, Hayrabedyan S, Todorova K. , et al. PreImplantation factor (PIF*) regulates systemic immunity and targets protective regulatory and cytoskeleton proteins. Immunobiology 2016; 221 (07) 778-793
    CrossrefPubMedGoogle Scholar
  • 200 O'Brien C, Barnea ER, Martin P. , et al. A Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to investigate the safety and pharmacokinetics of synthetic PreImplantation factor (sPIF), a novel immune-modulating biologic, in autoimmune hepatitis. AASLD conference abstract. Hepatology 2016; 63: 815A-816A
    PubMedGoogle Scholar
  • 201 Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JJ. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989; 337 (6203): 181-184
    CrossrefPubMedGoogle Scholar
  • 202 Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp 2003; 252: 279-286 ; discussion 286–290
    PubMedGoogle Scholar
  • 203 Ochi H, Abraham M, Ishikawa H. , et al. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci 2008; 274 (1–2): 9-12
    CrossrefPubMedGoogle Scholar
  • 204 Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med 2008; 14 (05) 528-535
    CrossrefPubMedGoogle Scholar
  • 205 Herold KC, Hagopian W, Auger JA. , et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346 (22) 1692-1698
    CrossrefPubMedGoogle Scholar
  • 206 Herold KC, Gitelman SE, Masharani U. , et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54 (06) 1763-1769
    CrossrefPubMedGoogle Scholar
  • 207 Keymeulen B, Vandemeulebroucke E, Ziegler AG. , et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352 (25) 2598-2608
    CrossrefPubMedGoogle Scholar
  • 208 Lied GA, Berstad A. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol 2011; 73 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 209 Migita K, Abiru S, Maeda Y. , et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007; 68 (07) 586-591
    CrossrefPubMedGoogle Scholar
  • 210 Nishikawa H, Enomoto H, Iwata Y. , et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-γ-inducible protein-10 in autoimmune hepatitis. Medicine (Baltimore) 2016; 95 (12) e3194
    CrossrefPubMedGoogle Scholar
  • 211 Czaja AJ. Management of recalcitrant autoimmune hepatitis. Curr Hepat Rep 2013; 12: 66-77
    CrossrefPubMedGoogle Scholar
  • 212 Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002; 6 (03) 799-824
    CrossrefPubMedGoogle Scholar
  • 213 Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995; 12 (05) 348-357
    CrossrefPubMedGoogle Scholar